,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny breast04', 'breast']
amazing to witness standing ovation at #asco22 for the results of destiny breast04 which completely redefine how we think about her2 analyses in clinical practice. bravo! 
Breast Medical Oncologist - @MayoClinic. Focus on #TNBC and #immunoonc. Opinions are mine, not my employer’s. Orgullosamente ecuatoriano ????